Low-Dose Ipilimumab in Combination With Nivolumab or Pembrolizumab for the Treatment of Advanced Melanoma


( Last Updated : August 2, 2022)
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1441-000

Details


Question

  1. What is the clinical effectiveness of low-dose ipilimumab in combination with nivolumab for the treatment of advanced melanoma?
  2. What is the clinical effectiveness of low-dose ipilimumab in combination with pembrolizumab for the treatment of advanced melanoma?
  3. What is the cost-effectiveness of low-dose ipilimumab in combination with nivolumab for the treatment of advanced melanoma?
  4. What is the cost-effectiveness of low-dose ipilimumab in combination with pembrolizumab for the treatment of advanced melanoma?

Key Message

The review did not find any studies exclusively on the clinical effectiveness and safety of low-dose ipilimumab in combination with nivolumab for the treatment of advanced melanoma that met the criteria for this review.

The review found limited evidence, from 1 single-arm phase II trial of 70 adults and 1 retrospective cohort study of 9 adults, on the clinical benefits and safety of low-dose ipilimumab in combination with pembrolizumab (or nivolumab for an unspecified number of patients in the retrospective cohort study) for the treatment of advanced melanoma.

In the single-arm study, 20 of 70 enrolled patients (29%) achieved a confirmed response, including 5 complete (7.2%) and 15 partial responses (21.4%). In the retrospective cohort study, 3 of 9 patients (33%) achieved a partial response.

The review did not find any studies on the cost-effectiveness of low-dose ipilimumab in combination with nivolumab or pembrolizumab for the treatment of advanced melanoma that met our criteria for this review.